Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma

Sivasundaram Karnan1, Akinobu Ota1, Hideki Murakami2, Md Lutfur Rahman3, Muhammad Nazmul Hasan1, Md Wahiduzzaman1, Ichiro Hanamura3, Lam Quang Vu3, Akihito Inoko2, Toshinori Hyodo1, Hiroyuki Konishi1, Shinobu Tsuzuki1 and Yoshitaka Hosokawa1

Abstract
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleura that is currently incurable due to the lack of an effective early diagnostic method and specific medication. The CDKN2A (p16) and NF2 genes are both frequently mutated in MPM. To understand how these mutations contribute to MPM tumor growth, we generated NF2/p16 double-knockout (DKO) cell clones using human MeT-5A and HOMC-B1 mesothelial cell lines. Cell growth and migration activities were significantly increased in DKO compared with parental cells. cDNA microarray analysis revealed differences in global gene expression profiles between DKO and parental cells. Quantitative PCR and western blot analyses showed upregulation of CD24 concomitant with increased phosphorylation of AKT, p70S6K, and c-Jun in DKO clones. This upregulation was abrogated by exogenous expression of NF2 and p16. CD24 knockdown in DKO cells significantly decreased TGF-β1 expression and increased expression of E-cadherin, an epithelial–mesenchymal transition marker. CD24 was highly expressed in human mesothelioma tissues (28/45 cases, 62%) and associated with the loss of NF2 and p16. Public data analysis revealed a significantly shorter survival time in MPM patients with high CD24 gene expression levels. These results strongly indicate the potential use of CD24 as a prognostic marker as well as a novel diagnostic and therapeutic target for MPM.

Introduction
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleura that is associated with asbestos exposure after 30–40 years of latency1,2. Patients with MPM are usually diagnosed at an advanced stage of the disease and their prognosis remains poor. The median survival after diagnosis is 6–12 months and the standard treatment agents, pemetrexed and cisplatin, are relatively ineffective at increasing survival time2,3. Despite the restricted and banned use of asbestos, MPM is increasingly being diagnosed in young individuals and women4,5. Other risk factors, including exposure to erionite fibers, therapeutic ionizing radiation to the chest, and germline BRCA1-associated protein 1 (BAP1)-inactivating mutations, have been causally linked to MPM1. Therefore, new therapies based on improving patient survival are still required6,7.

Molecular biological studies in MPM have revealed frequent genetic alterations of tumor suppressor genes, including neurofibromatosis 2 (NF2), cyclin-dependent kinase inhibitor 2A (p16), and BAP18–15. Furthermore, multiplex molecular analyses with whole-exome sequencing, high-density array comparative genomic hybridization, and immunohistochemistry (IHC) have disclosed that somatic
BAP1 mutations and deletions were present in >60% of MPM patients.16,17 We recently reported that fibroblast growth factor receptor 2 is highly expressed in NF2-knockout mesothelial cell lines and is a candidate molecule for the development of therapeutic and diagnostic strategies targeting MPM.18 A previous study using NF2 and p16 double-knockout (DKO) mice indicated that these genes, when mutated, contribute to mesothelioma development.19 However, it remains unclear how these complex mutations contribute to tumor formation in MPM. We established NF2/p16-DKO cell clones in human immortalized mesothelial cell lines and identified several genes regulated by NF2 and p16.

CD24 is a glycosylphosphatidylinositol-linked sialoprotein that was shown to be present in the cell membranes of B lymphocyte precursors, neutrophils, neuronal cells, and some epithelial cells, and is highly expressed in several types of cancers.20–30 It was also shown to be an independent prognostic marker of reduced patient survival in ovarian cancer and non-small cell lung cancer.21,22 Furthermore, CD24 is reportedly related to epithelial–mesenchymal transition (EMT) in ovarian and pancreatic cancers.31,32 The present study found that CD24 is highly expressed in NF2/16-DKO cell clones and human MPM tissues, highlighting it as a potential diagnostic and therapeutic target for MPM.

Results
NF2/p16 DKO enhances cell proliferation, colony formation, and migration in MeT-5A and HOMC-B1 human mesothelial cell lines

To investigate the roles of NF2 and p16 in mesothelial cells, we established two NF2-knockout clones (NF2-KO #1 and #2), two p16-knockout clones (p16-KO #1 and #2), and two NF2/p16-DKO cell clones (DKO #1 and #2) using MeT-5A and HOMC-B1 human mesothelial cell lines with the CRISPR/Cas9 system (Fig. 1a). Protein expression of NF2 and p16 was not detected in DKO #1 and #2 (Fig. 1b). Also, no p14ARF expression, an alternative form of p16, was detected after targeting exon 1 of p16 (Fig. 1b). We examined cell proliferation of the established clones using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and found that the cell growth ratio was significantly increased in the DKO clones compared with that in the parental cells (Fig. 2a). The DKO clones also formed more colonies in soft agar compared with the parental cells (Fig. 2b). Furthermore, migration activity was significantly higher in the DKO clones (Fig. 2c). These results indicate that NF2/p16 inactivation enhances cell growth, clonogenicity, and migration in the mesothelial cells.

Gene expression change induced by disruption of NF2/p16

To identify genes involved in enhanced cell growth and migration, we performed comprehensive cDNA microarray analysis in the DKO, NF2-KO, and p16-KO clones, as well as the parental cells. To compare gene expression profiles, normalized values of raw microarray data were calculated and clustered according to differential gene expression. Expression of 29 genes was upregulated >20.0-fold (Supplementary Table S3) and 76 genes were downregulated <0.05-fold (Supplementary Table S4). Clustering of the 105 genes showed a distinct gene expression pattern among the DKO, NF2-KO, and p16/p14-KO clones, and the parental cells (Fig. 3a). To further confirm the effect of NF2/p16 on changes to gene expression, we generated clones exogenously expressing NF2 in the NF2-KO clone (exogenous NF2/NF2-KO), exogenous NF2 in the p16-KO clone (exogenous p16/p16-KO), exogenous NF2 and p16 in the DKO clone (exogenous NF2 and p16/DKO). We then performed quantitative real-time PCR (qRT-PCR) analysis for four cell surface receptor genes (PTN, CD24, BMP7, and CADM1), because their protein products are easily detectable by molecular diagnosis and are also related to cell survival, proliferation, or tumor growth. The qRT-PCR results revealed increased expression of PTN, CD24, BMP7, and CADM1 genes in the DKO clones compared with the parental cells and NF2-KO and p16-KO clones (Fig. 3b). Furthermore, increased expression of PTN, CD24, and BMP7 was abrogated in the DKO clones exogenously expressing NF2 and p16 (exogenous NF2 and p16/DKO) (Fig. 3b), strongly suggesting that the affected gene products were downstream of NF2 and p16 signaling.

Effect of NF2/p16 DKO on CD24 expression and cell cycle-related molecules

CD24 has been implicated in the pathogenesis of a wide range of human cancers and emerged as a novel anticancer application in a panel of solid cancers.33–36 Therefore, we focused on CD24 as its expression was increased in DKO cells (Fig. 4a). Exogenous expression of NF2 and p16 resulted in reduced CD24 expression in NF2 and p16/DKO clones (Fig. 4a), indicating that CD24 expression is negatively regulated by NF2/p16 signaling in mesothelial cells.

Next, the phosphorylation levels of AKT, p70S6K, and c-Jun were investigated and quantified to determine cell growth signaling. As shown in Fig. 4a, b, we observed increased phosphorylation of cellular growth and proliferation-related signaling molecules, including AKT, p70S6K, and c-Jun, in the DKO clones. PTN, BMP7, and CADM1 protein products, as well as CD24, were increased in the DKO clones (Fig. 4a). To confirm the effect of NF2 and p16 on the expression of these signaling proteins, we utilized DKO clones exogenously expressing NF2 and p16 (exogenous NF2 and p16/DKO) (Fig. 4a). In the exogenous NF2 and p16/DKO clones, increased expression of CD24, PTN, BMP7, CADM1, p-pAKT, p-p70S6K, and p-c-Jun was downregulated, strongly
suggesting that these proteins function downstream of NF2 and p16 signaling. Different expression patterns between CADM1 mRNA and its protein were observed in HOMC-B1 cells. Different expression patterns of PTN and BMP7 proteins from their mRNAs in MeT-5A and HOMC-B1 cells were also observed. The difference would be, in part, due to a post-transcriptional modification.

**CD24 knockdown downregulates TGF-β1 and cell proliferation in the absence of NF2/p16 gene expression**

To investigate the involvement of CD24 in cell proliferation, we knocked down CD24 in the DKO clones and parental cells. MTT assay showed that cell growth was significantly decreased in the CD24 shRNA-DKO cells compared with the DKO clones (Fig. 5a). Furthermore, colony formation also decreased in the CD24 shRNA-DKO cells (Supplementary Fig. S1). These results strongly suggest that CD24 may play an important role in cell growth and clonogenicity of mesothelioma cells with loss of p16 and NF2 expression.

In DKO cell clones, we observed gene expression changes characteristic of EMT phenotypes, such as increased expression of transforming growth factor-β1 (TGF-β1) (as an inducer of EMT phenotypes), and Snail and N-cadherin (as mesenchymal markers). Notably, CD24 knockdown decreased expression of TGF-β1, Snail, and N-cadherin, and increased expression of E-cadherin in DKO clones (Fig. 5b), strongly suggesting that CD24 may be related to the EMT phenotype. The TGF-β1 inhibitor, vactosertib, did not affect expression of CD24 in DKO clones, implying that CD24 functions upstream of TGF-β1 expression (Fig. 5c). Increased phosphorylation of

---

**Fig. 1 Generation of NF2-knockout (NF2-KO), CDKN2A-knockout (p16-KO), and NF2/p16 double-knockout (NF2/p16-DKO) cell clones using a CRISPR/Cas9 system with the MeT-5A and HOMC-B1 human mesothelial cell lines.**

**a** Single-guide RNA sequences were designed against exon 8 of the NF2 gene (left side) and exon 1 of the CDKN2A (p16) gene (right side). **b** Independent NF2-knockout clones (NF2-KO#1 and #2), p16-knockout clones (p16-KO#1 and #2), and NF2/p16-DKO clones (DKO#1 and #2) were established. NF2 and p16/14 protein expression was determined by western blot analysis. GAPDH was used as an internal standard.
Fig. 2 (See legend on next page.)
SMAD2 in DKO cells compared to parental cells and subsequent decrease after treatment with the inhibitor were also observed (Fig. 5c). Furthermore, DKO clones with higher CD24 expression showed a spindle cell morphology, which is a morphological feature of EMT (Fig. 5d). Knockdown of CD24 also led to a change in cell morphology from spindle cell to circle shape, as well as an increased number of cell–cell contacts. To obtain further experimental evidence for the EMT phenotype, immunofluorescence analyses were performed to examine the expression of desmoplakin, one of the desmosomes. A loss of desmoplakin expression in DKO cells and a mesothelioid type. To further validate frequency of CD24 expression was observed in the epithelial, sarcomatous, and biphasic subtypes (epithelioid, sarcomatous, and biphasic) is summarized in Table S5. A high frequency of CD24 expression was observed in the epithelioid type. To further validate CD24 expression in MPM patients, we analyzed a public cohort of 86 patients from The Cancer Genome Atlas Mesothelioma. Our analysis revealed that overall survival in MPM patients with higher CD24 expression levels was shorter than that in those with low CD24 expression levels (Fig. 6c). According to the log2 value of CD24 probe, patients were divided into two groups: high (log2 value > 6.938, n = 42) and low (log2 value < 6.938, n = 44) CD24 expression. Thus, high CD24 expression was significantly associated with overall survival (P < 0.0001).

Furthermore, NF2 and p16 expression, together with CD24 expression in human MPM tissue arrays, was immunohistochemically examined. CD24-positive expression showed 20 (100%) of 20 cases with both NF2- and p16-negative expression, whereas CD24-positive expression showed 8 (42%) of 19 cases with both NF2- and p16-positive expression (Supplementary Table S6 and Supplementary Fig. S3). These results suggest that CD24-positive expression might be associated with the loss of NF2 and p16 expression in MPM tissues.

Discussion
NF2, p16, and BAP1 are the three major tumor suppressor genes that frequently undergo genomic alterations in MPMs. In the present study, we generated both NF2 and p16-knockout isogenic clones using the human normal mesothelial cell lines, MeT-5A and HOMC-B1, and showed that loss of NF2 and p16 expression enhanced cell growth, clonogenicity, and migration activities with global changes in gene expression. Our findings strongly suggest that CD24 expression occurs downstream of NF2 and p16 in mesothelial cells and is correlated with overall survival of MPM patients.

CD24 is frequently overexpressed in several types of solid tumors and is correlated with poor prognosis. Thus, CD24 could be a potential target for a monoclonal antibody-mediated therapy. Antibody-mediated therapy toward cell surface antigens, such as CD20, has been used as treatment for non-Hodgkin’s lymphoma. Therefore, the present study focused on CD24, as its expression is increased in DKO clones. Knockdown of CD24 reduced cell growth and clonogenicity. CD24 was also reported to be related to EMT, which is an important step leading to invasion, migration, and resistance to apoptosis of various cancer cells. EMT phenotypes are characterized by decreased expression of E-cadherin as an epithelial marker, and increased expression of TGF-β1 as an inducer of EMT and Snail, Twist, Slug, vimentin, and N-cadherin as mesenchymal markers, and are responsible for poor prognosis in patients with various cancers. In the present study, knockdown of CD24 decreased the expression of TGF-β1, Snail, and N-cadherin, and increased the expression of E-cadherin in DKO clones, strongly suggesting that CD24 may contribute to the EMT phenotype in the mesothelial cells. To further explore the relationship between CD24 and TGF-β1, we examined the effect of TGF-β1 inhibitor in the DKO cells. Knockdown of CD24 decreased the
Fig. 3 Gene expression analysis. Parental MeT-5A cells and knockout cell clones were seeded in 6-well plates and incubated for 24 h. Total RNA was extracted and cDNA microarray analysis was performed using Agilent Whole Human Genome cDNA Microarray Kit (4 × 44 K; Design ID, 026652).

a Heat map showing upregulated genes (29 genes; fold change > 20.0) and downregulated genes (76 genes, fold change < 0.05) in the DKO cell clones compared with the parent cells, NF2-KO cell clones, and p16-KO cell clones. The heat map was constructed using normalized values of each sample with Tree View (Cluster 3.0) software. Corresponding upregulated or downregulated genes in the heat map are shown on the right side.

b Quantitative real-time PCR (qRT-PCR) analysis. Four genes that were upregulated in DKO cell, as detected using cDNA microarray analysis, were selected for qRT-PCR analysis using the SYBR green method. Relative gene expression levels are shown after normalization to GAPDH mRNA expression. Mean values were compared with the normal control value to calculate the relative amounts of transcripts. Data represent mean ± SEM (n = 3). Asterisks (*) indicate statistically significant differences (*P < 0.05).
expression of TGF-β1; however, TGF-β1 inhibitor did not alter the expression of CD24, indicating that CD24 functions upstream of TGF-β1. In addition, DKO clones with higher expression of CD24 showed a spindle cell morphology, which is a morphological feature of EMT. We also observed that knockdown of CD24 changed the morphology of spindle cells to circles. Thus, our results suggest that CD24 contributes to EMT phenotypes in mesothelial cells. Our results indicate that CD24 expression is closely associated with changes in both gene
Fig. 5 (See legend on next page.)
expression and cell morphology characteristic of EMT phenotypes. Desmosome is a cell structure specialized for cell-to-cell adhesion. The loss of expression of many desmosome proteins has been reported in different cancers and may contribute to EMT. Thus, the expression of desmoplakin, one of the desmosomes, was analyzed, and loss of desmoplakin expression was found in DKO cells and mesothelioma cell lines, providing further experimental evidence for the EMT phenotype; therefore, we propose that CD24 expression induces the EMT phenotypes involved in the pathogenesis of MPM.

IHC analysis showed that CD24 was commonly expressed in 62% of human MPM tissues. Furthermore, analysis of public data revealed that MPM patients with higher expression of the CD24 gene showed a significantly shorter survival time. In addition, loss of NF2 and p16 resulted in increased expression of CD24, and subsequent rescue of the two genes decreased its expression in the MeT-5A and HOMC-B1 cell lines. More importantly, CD24 expression was associated with the loss of NF2 and p16 expression in human MPM tissues. These results indicate that CD24 expression is intimately regulated by NF2 and p16 expression. Furthermore, knockdown of CD24 in the DKO clones led to retardation of cell growth and colony formation, strongly suggesting that CD24 may play a pivotal role in the proliferation and clonogenicity of DKO cells.

In the present study, global gene expression changes in response to loss of NF2 and p16 in the MeT-5A and HOMC-B1 human mesothelial cell lines were demonstrated. CRISPR/Cas9-mediated loss of NF2 and p16 enhanced cell proliferation and CD24 expression, and disruption of CD24 reduced the proliferation of the cells. Although the molecular mechanisms underlying the upregulation of CD24 via loss of NF2 and p16 remain unclear, CD24 was commonly expressed in MPM tissues and was associated with poor prognosis of MPM patients. Therefore, CD24 may be used as a prognostic marker as well as a novel diagnostic and therapeutic target for MPM. Further studies are warranted to develop a new therapeutic approach for the treatment of MPM.

Materials and methods

Cell culture

The immortalized normal human mesothelial cell lines, MeT-5A (pleural mesothelial) and HOMC-B1 (omental mesothelial; epithelioid type), and mesothelioma cell lines (Y-MESO-9) were kindly provided by Dr. Y. Sekido at the Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan. The HOMC-B1 cell line was maintained as described previously. The MeT-5A was maintained in RPMI-1640 (Wako, Osaka, Japan) medium containing 10% fetal bovine serum (Sigma) and 1% penicillin/streptomycin (Wako) at 37 °C in a 5% CO2 humidified atmosphere.

Gene knockout using the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system

The CRISPR/Cas9 system was used to disrupt expression of the NF2 and CDKN2A(p16) genes as described previously. pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid #48138). In brief, a single-guide RNA (sgRNA) sequence was selected using an optimized CRISPR design (http://crispr.mit.edu/). The sgRNA sequence used for NF2 was 5′-AAACATCTCGTACAGTGACA-3′ and the sequence used for p16 was 5′-ACCGTAACTATTCGGTGCGT-3′, corresponding to exons 8 and 1, respectively. Plasmids expressing hCas9 and the sgRNA were prepa
### Table 1  Summary of immunohistochemistry in this study.

| Case nos. | Age  | Sex | Organ (anatomic site) | Pathology diagnosis | Stage | CD24 intensity | Proportion (%) |
|-----------|------|-----|-----------------------|---------------------|-------|----------------|----------------|
| 1         | 64   | M   | Thoracic cavity       | Malignant mesothelioma of chest wall | I     | 1+             | 100            |
| 2         | 48   | M   | Thoracic cavity       | Malignant mesothelioma of right pleura | I     | 0              | -              |
| 3         | 58   | F   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 2+             | 100            |
| 4         | 49   | F   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 2+             | 60             |
| 5         | 22   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 1+             | 60             |
| 6         | 49   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 3+             | 100            |
| 7         | 32   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 2+             | 100            |
| 8         | 29   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | I     | 2+             | 60             |
| 9         | 31   | F   | Thoracic cavity       | Malignant mesothelioma of thoracic cavity | I     | 2+             | 100            |
| 10        | 70   | F   | Thoracic cavity       | Malignant mesothelioma of right pleura | II    | 2+             | 100            |
| 11        | 47   | M   | Thoracic cavity       | Malignant mesothelioma of left pleura | II    | 0              | -              |
| 12        | 60   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | II    | 3+             | 100            |
| 13        | 46   | M   | Thoracic cavity       | Malignant mesothelioma of thoracic cavity | II    | 2+             | 100            |
| 14        | 35   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | II    | 0              | -              |
| 15        | 83   | M   | Thoracic cavity       | Malignant mesothelioma of pleura     | III   | 0              | -              |
| 16        | 56   | M   | Thoracic cavity       | Malignant mesothelioma of pleura mediastinalis | III   | 0              | -              |
| 17        | 67   | F   | Thoracic cavity       | Malignant mesothelioma of right thoracic cavity | IV    | 3+             | 100            |
| 18        | 57   | M   | Abdominal cavity      | Malignant mesothelioma of peritoneum | I     | 3+             | 100            |
| 19        | 29   | M   | Abdominal cavity      | Malignant mesothelioma of peritoneum | I     | 0              | -              |
| 20        | 71   | M   | Abdominal cavity      | Malignant mesothelioma of mesostenium | II    | 2+             | 100            |
| 21        | 63   | F   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 2+             | 100            |
| 22        | 48   | F   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 2+             | 100            |
| 23        | 60   | F   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 2+             | 100            |
| 24        | 60   | F   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 0              | -              |
| 25        | 47   | M   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 2+             | 100            |
| 26        | 33   | F   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 1+             | 100            |
| 27        | 76   | F   | Abdominal cavity      | Malignant mesothelioma of hypogastrum | II    | 3+             | 100            |
| 28        | 78   | M   | Abdominal cavity      | Malignant mesothelioma of hypogastrum | II    | 1+             | 100            |
| 29        | 41   | F   | Abdominal cavity      | Malignant mesothelioma of hypogastrum | II    | 0              | -              |
| 30        | 28   | M   | Abdominal cavity      | Malignant mesothelioma of left retroperitoneum | II   | 2+             | 100            |
| 31        | 5    | F   | Abdominal cavity      | Malignant mesothelioma of right superior belly | II   | 2+             | 100            |
| 32        | 45   | M   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 1+             | 100            |
| 33        | 69   | M   | Abdominal cavity      | Malignant mesothelioma of peritoneum | II    | 3+             | 100            |
| 34        | 78   | M   | Abdominal cavity      | Malignant mesothelioma of hypogastrum | III   | 2+             | 100            |
| 35        | 33   | M   | Abdominal cavity      | Malignant mesothelioma of retroperitoneum | III   | 0              | -              |
| 36        | 5    | F   | Abdominal cavity      | Malignant mesothelioma of abdominal cavity | III   | 1+             | 100            |
| 37        | 40   | F   | Heart                | Malignant mesothelioma of left cardiac atrium | II    | 0              | -              |
| 38        | 50   | F   | Heart                | Malignant mesothelioma of left cardiac atrium | II    | 2+             | 100            |
| 39        | 43   | F   | Heart                | Malignant mesothelioma of pericardium | II    | 2+             | 100            |
The NF2/pcDNA3.1 vector was transfected into NF2-KO clones, the p16/pcDNA3.1 vector was transfected into p16-KO clones, and the NF2/pcDNA3.1 and p16/pcDNA3.1 vectors were transfected into DKO clones using the 4D-Nucleofector System. After transfection, cells were incubated for 48 h, washed with phosphate-buffered saline (PBS), and lysed in loading buffer. The lysates were used for Western blot analysis.

Quantitative real-time PCR

qRT-PCR analysis for PTN, CD24, BMP7, and CADM1 was performed using SYBR Green I as previously described. Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control. The sequences of the primers for PTN, CD24, BMP7, and CADM1 used in this study are summarized in Supplementary Table S1.

cDNA microarray analysis

cDNA microarray analysis was performed according to the manufacturer’s instructions (Agilent Technologies). In brief, cDNA synthesis and cRNA labeling with cyanine 3 (Cy3) dye were performed using the Agilent Low Input Quick Amp Labeling Kit (Agilent Technologies). Cy3-labeled cRNA was purified, fragmented, and hybridized on a Human Gene Expression 4 × 44K v2 Microarray Chip containing 27,958 Entrez Gene RNAs using a Gene Expression Hybridization kit (Agilent Technologies). Raw and normalized microarray data were submitted to the Gene Expression Omnibus database at the National Center for Biotechnology Information (accession number GSE116000; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116000). Gene set enrichment analysis was performed according to the instructions.

Cell growth assay

Cell growth rate was determined using MTT assay. Briefly, cells (1 × 10³ per well) were seeded into 96-well plates and cultured for the indicated times. Subsequently, 10 µL of MTT solution (5 mg/mL; Sigma-Aldrich) was added to each well and cells were further incubated for 4 h. Next, cell lysis buffer was added to the wells to dissolve the colored formazan crystals produced by MTT. The relative optical density (OD) at 595 nm was calculated by dividing the OD on day 0 at each time point (days 0, 1, 3, 5, and 7). The absorbance was measured at 595 nm using a SpectraMAX M5 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).

Soft agar colony formation assay

Soft agar colony formation assay was performed as described previously. Then, cells (200 per well) were seeded in 6-well plates. After 14 days, the cells were stained with MTT and imaged. The number of colonies was counted using Colony Counter software (Keyence, Tokyo, Japan). Data are presented as mean ± SEM (n = 3).

Migration assay

Cells (2.5 × 10⁵ per well) were seeded in Boyden chambers in 24-well plates (8 µm for 24-well plates; Milipore, Tokyo, Japan) and the culture medium was added into the lower chambers. After 24 h, cells were stained with crystal violet and imaged. The number of colonies was counted manually under a microscope.

Western blot analysis

Western blot analysis was performed as described previously. The antibodies used are listed in Supplementary Table S2. Immune complexes were detected using Immuno Star LD (Wako Pure Chemical Industries, Ltd, Osaka, Japan) in conjunction with a LAS-4000 image analyzer (GE Healthcare, Tokyo, Japan).

Immunohistochemistry

IHC analysis was performed as previously described. Human malignant mesothelioma tissue arrays were
purchased (MS-1001a; Biomax, Houston, TX, USA). Sections were reacted with a primary antibody (CD24 antibody, 2 μg/mL; NF2 antibody, 2 μg/mL; p16 antibody, 2 μg/mL; CADM1 antibody, 2 μg/mL; Ki-67 antibody, 2 μg/mL and hematoxylin and eosin). Normal rabbit immunoglobulin G and omission of primary antibodies were used as negative controls. Immunoreactivity was independently evaluated by two investigators (S.K. and H.M.). The intensity of staining was scored as strong (3+), moderate (2+), weak (1+), or negative (0). The number of cases and their staining intensities are shown in the right panel. Kaplan–Meier analysis was conducted to assess the value of CD24 in overall survival of MPM patients in TCGA mesothelioma obtained from the UCSC Xena database. Fluorescence values above the median were considered high CD24 expression, whereas fluorescence values below the median were considered low CD24 expression. Scale bar = 100 μm.

**Fig. 6 Immunohistochemical (IHC) analysis of CD24 expression.** a Representative IHC results showing CD24 expression in two MPM tissues (right panels, cases 6 and 33) and two normal mesothelium tissues (left panels, cases 46 and 47). b Summary of IHC results in MPM tissues. Immunoreactivity was independently evaluated by two investigators (S.K. and H.M.). Staining intensity was scored as strong (3+), moderate (2+), weak (1+), or negative (0). The number of cases and their staining intensities are shown in the right panel. c Kaplan–Meier analysis was conducted to assess the value of CD24 in overall survival of MPM patients in TCGA mesothelioma obtained from the UCSC Xena database. Fluorescence values above the median were considered high CD24 expression, whereas fluorescence values below the median were considered low CD24 expression. Scale bar = 100 μm.
fixed using 4% paraformaldehyde solution for 20 min at room temperature. Cells were permeabilized with PBS containing 0.1% Triton X-100 and blocked using PBS containing 7% serum for 30 min. Then, cells were incubated with γ-catenin (desmoplakin; BD Transduction Laboratories, San Jose, CA, USA; 1:100 dilution) for 2 h at room temperature followed by fluorescence staining with anti-mouse IgG Alexa Fluor® 594 (Abcam, Cambridge, UK; 1:200 dilution) and Hoechst (Dojinbo, Kumamoto, Japan; 1:200 dilution) for 1 h at room temperature. Images were acquired using BZ-II (Keyence) with a fluorescence microscope (BZ-X9000; Keyence).

Statistical analysis

The statistical significance between groups was determined using one-way analysis of variance and Dunnett’s comparison. Statistical analyses were performed using SPSS 23.0 program (SPSS, Inc., Chicago, Illinois, USA). Results are expressed as mean ± SEM.

Acknowledgements

We thank Dr. Y. Sekido, Division of Molecular Oncology, Aichi Cancer Center Research Institute, for providing normal mesothelial cell line (MeT-5A). This research was partly supported by Hirose International Scholarship foundation and Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science [19K09292 and 19K08668].

Author details

Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. 2Department of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. 3Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of this article (https://doi.org/10.1038/s41420-020-00364-1) contains Supplementary Material, which is available to authorized users.

Received: 11 June 2020 Revised: 28 September 2020 Accepted: 30 October 2020 Published online: 18 November 2020

References

1. Carbone, C. et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 69, 402–429 (2019).
2. Patel, S. C. & Dowell, J. E. Modern management of malignant pleural mesothelioma. Lung Cancer 77, 63–72 (2016).
3. Vogelzang, N. J. et al. Phase II study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003).
4. Carbone, M. et al. Consensus report of the 2015 Weinman International Conference on Mesothelioma. J. Thorac. Oncol. 11, 1246–1262 (2016).
5. Carbone, M. & Bedrosian, C. W. The pathogenesis of mesothelioma. Semin. Diagn. Pathol. 23, 56–60 (2006).
6. Fung, H., Kow, Y. W., Van, H. B. & Mossman, B. T. Patterns of 8-hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in rat and human pleural mesothelial cells after exposure to crocidolite asbestos. Carcinogenesis 18, 825–832 (1997).
7. Sekido, Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34, 1413–1419 (2013).
8. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011).
9. Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 loss in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011).
10. Guo, G. et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF1, CDKN2A, and CDH1 in malignant pleural mesothelioma. Cancer Res. 75, 264–269 (2015).
11. Cheng, J. Q. et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54, 5547–5551 (1994).
12. Thumney, C. et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64, 140–147 (2009).
13. Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92, 10854–10858 (1995).
14. Shefford, B. S. et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am. J. Surg. Pathol. 39, 977–982 (2015).
15. Farzin, M. et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47, 302–307 (2015).
16. Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10, 565–576 (2015).
17. Yoshikawa, Y. et al. High-density array-CGH with targeted NGS unmasks multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc. Natl Acad. Sci. USA 113, 13452–13457 (2016).
18. Wahiduzzaman, M. et al. Establishment and characterization of CRISPR/Cas9-mediated NF2(-/-) human mesothelial cell line: molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 110, 180–193 (2019).
19. Kukuyan, A. M. et al. Inactivation of Bap1 cooperates with losses of NF2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 79, 4113–4123 (2019).
20. Schabath, H., Runz, S., Journaa, S. & Altevogt, P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell Sci. 119, 314–325 (2006).
21. Kristiansen, G. et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 161, 1215–1221 (2002).
22. Kristiansen, G. et al. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br. J. Cancer 88, 231–236 (2003).
23. Ayte, D. C. et al. CD24 induces changes to the surface receptors of B cell microvesicles with variable effects on their RNA and protein cargo. Sci. Rep. 7, 8642 (2017).
24. Deng, J. et al. CD24 expression as a marker for predicting clinical outcome in human gliomas. J. Biomed. Biotechnol. 2012, 517172 (2012).
25. Kristiansen, G. et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906–4913 (2003).
26. Sano, A. et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 16, 506–514 (2009).
27. Jacob, J. et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4, 454–460 (2004).
28. Su, M. C., Hsu, C., Kao, H. L. & Jeng, Y. M. CD24 expression is a prognostic factor in antineoplastic, cholangiocarcinoma. Cancer Lett. 235, 34–39 (2006).
29. Lu, S. et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 9, e646 (2018).
30. Tanaka, T. et al. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer. Oncol. Rep. 34, 2282–2288 (2015).
31. Nakamura, K. et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol. Rep. 37, 3189–3200 (2017).
32. Lubesder-Martellato, C. et al. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget 7, 49156–49168 (2016).
33. Salnikov, A. V. et al. Antibody targeting of CD24 efficiently retards growth and influences cytotoxicity in experimental carcinomas. Br. J. Cancer 108, 1449–1459 (2013).
34. Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).
35. Chan, S. H. et al. Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer. Mol. Cancer Ther. 18, 147–161 (2019).
36. Eyvazi, S., Kazemi, B., Dastmalchi, S. & Bandehpour, M. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Curr. Cancer Drug Targets 18, 328–336 (2018).
37. Kowalczuk, A. P. & Green, K. J. Structure, function, and regulation of desmosomes. Prog. Mol. Biol. Transl. Sci. 116, 95–118 (2013).
38. Arik, D., Can, C., Dündar, E., Kabukcuoglu, S. & Pasaoğlu, Ö. Prognostic significance of CD24 in clear cell renal cell carcinoma. Pathol. Oncol. Res. 23, 409–416 (2017).
39. Yamazaki, H. et al. Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 419, 529–536 (2012).
40. Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90, 2188–2195 (1997).
41. Leget, G. A. & Czuczmar, M. S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548–551 (1998).
42. Aruga, N. et al. Epithelial-mesenchymal transition (EMT) is correlated with patient’s prognosis of lung squamous cell carcinoma. Tokai J. Exp. Clin. Med. 43, 5–13 (2018).
43. Hurz, K., Zeiler, J., Sachs, L., Ormanns, S. & Spindler, V. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Mol. Carcinog. 56, 1884–1895 (2017).
44. Shiina, H. et al. Functional loss of the γ-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 65, 2130–2138 (2005).
45. Dubash, A. D. & Green, K. J. Desmosomes. Curr. Opin. 21, RS29–RS31 (2011).
46. Kakuchi, T. et al. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis 37, 1098–1109 (2016).
47. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
48. Yamaji, M. et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6, 2646–2659 (2017).
49. Wahiduzzaman, M. et al. Novel combined Ato-C treatment synergistically suppresses proliferation of bcr-abl-positive leukemic cells in vitro and in vivo. Cancer Lett. 433, 117–130 (2018).
50. Ito, T. et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 107, 1527–1538 (2016).